1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 32, 08/Aug/2024
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

Background

A new respiratory virus surveillance platform, based on nationwide hospital laboratory data, was established in Israel during the COVID-19 pandemic.

Aim

We aimed to evaluate the performance of this platform with respect to the detection of influenza and respiratory syncytial virus (RSV) from week 36 in 2020 to week 15 in 2023, and how it fits with the World Health Organization (WHO) mosaic surveillance framework.

Methods

Data of respiratory samples from hospitalised patients sent for laboratory confirmation of influenza virus or RSV from 25 general hospital laboratories nationwide were collected. We analysed the weekly number and percentage of samples positive for influenza virus or RSV vis-à-vis SARS-CoV-2 activity and compared data from the new surveillance platform with existing surveillance platforms. Using data in the new surveillance platform, we analysed early stages of a 2021 out-of-season RSV outbreak and evaluated the capabilities of the new surveillance system with respect to objectives and domains of the WHO mosaic framework.

Results

The new hospital-laboratory surveillance platform captured the activity of influenza virus and RSV, provided crucial data when outpatient sentinel surveillance was not operational and supported an out-of-season RSV outbreak investigation. The new surveillance platform fulfilled important objectives in all three domains of the mosaic framework and could serve for gathering additional information to fulfil more domain objectives.

Conclusion

The new hospital laboratory surveillance platform provided essential data during the COVID-19 pandemic and beyond, fulfilled important domain objectives of the mosaic framework and could be adapted for the surveillance of other viruses.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.32.2300634
2024-08-08
2024-12-21
/content/10.2807/1560-7917.ES.2024.29.32.2300634
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/32/eurosurv-29-32-4.html?itemId=/content/10.2807/1560-7917.ES.2024.29.32.2300634&mimeType=html&fmt=ahah

References

  1. Mott JA, Bergeri I, Lewis HC, Mounts AW, Briand SC. Facing the future of respiratory virus surveillance: "The mosaic surveillance framework". Influenza Other Respir Viruses. 2023;17(3):e13122.  https://doi.org/10.1111/irv.13122  PMID: 36970570 
  2. Israel Center for Disease Control (ICDC). [Influenza season 2019-2020 summary report]. Ramat Gan: ICDC; 2020. Hebrew. Available from: https://www.gov.il/he/departments/publications/reports/flu2019-2020
  3. Glatman-Freedman A, Gur-Arie L, Sefty H, Kaufman Z, Bromberg M, Dichtiar R, et al. The impact of SARS-CoV-2 on respiratory syndromic and sentinel surveillance in Israel, 2020: a new perspective on established systems. Euro Surveill. 2022;27(16):2100457.  https://doi.org/10.2807/1560-7917.ES.2022.27.16.2100457  PMID: 35451365 
  4. Glatman-Freedman A, Bromberg M, Dichtiar R, Hershkovitz Y, Keinan-Boker L. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data. EBioMedicine. 2021;72(72):103574.  https://doi.org/10.1016/j.ebiom.2021.103574  PMID: 34537449 
  5. Glatman-Freedman A, Bromberg M, Hershkovitz Y, Sefty H, Kaufman Z, Dichtiar R, et al. Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel. Emerg Infect Dis. 2022;28(5):948-56.  https://doi.org/10.3201/eid2805.220141  PMID: 35361311 
  6. Israel Center for Disease Control (ICDC). Surveillance report on morbidity due to respiratory viruses, Week 15, ending 15/4/2023. Ramat Gan: ICDC; 2023. Available from: https://www.gov.il/BlobFolder/reports/flu-15042023/en/files_weekly-flu-corona_flu_en_flu-15042023e.pdf
  7. Central Bureau of Statistics. Census of population and housing. The 2008 Israel integrated census of population and housing. Jerusalem: Central Bureau of Statistics. 2008. Available from: https://www.cbs.gov.il/en/publications/Pages/journal/The-2008-Israel-Integrated-Census-of-Population-and-Housing.aspx
  8. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-60.  https://doi.org/10.1093/bioinformatics/btp324  PMID: 19451168 
  9. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;34(23):4121-3.  https://doi.org/10.1093/bioinformatics/bty407  PMID: 29790939 
  10. Tan L, Lemey P, Houspie L, Viveen MC, Jansen NJ, van Loon AM, et al. Genetic variability among complete human respiratory syncytial virus subgroup A genomes: bridging molecular evolutionary dynamics and epidemiology. PLoS One. 2012;7(12):e51439.  https://doi.org/10.1371/journal.pone.0051439  PMID: 23236501 
  11. World Health Organization (WHO). Crafting the mosaic. A framework for resilient surveillance for respiratory viruses of epidemic and pandemic potential. Geneva: WHO; 2023. Available from: https://cdn.who.int/media/docs/default-source/mosaic/who_mosaic_respiratory_surveillance_framework_2023.pdf
  12. Ibrahim NK. Epidemiologic surveillance for controlling Covid-19 pandemic: types, challenges and implications. J Infect Public Health. 2020;13(11):1630-8.  https://doi.org/10.1016/j.jiph.2020.07.019  PMID: 32855090 
  13. Hirsh S, Hindiyeh M, Kolet L, Regev L, Sherbany H, Yaary K, et al. Epidemiological changes of respiratory syncytial virus (RSV) infections in Israel. PLoS One. 2014;9(3):e90515.  https://doi.org/10.1371/journal.pone.0090515  PMID: 24594694 
  14. Centers for Disease Control and Prevention (CDC). National Center for Emerging and Zoonotic Infectious Diseases (NCEZID). HHS Protect - a common operating picture for COVID-19. Atlanta: CDC. [Accessed: 26 Jul 2023]. Available from: https://www.cdc.gov/orr/topics-programs/hhs-protect.html?CDC_AAref_Val
  15. Centers for Disease Control and Prevention (CDC). U.S. influenza surveillance: purpose and methods. Atlanta: CDC; 2023. Available from: https://www.cdc.gov/flu/weekly/overview.htm
  16. Centers for Disease Control and Prevention (CDC). FluView summary ending September 30, 2022. Atlanta: CDC; 2023. Available from: https://www.cdc.gov/flu/weekly/weeklyarchives2022-2023/week39.htm
  17. Centers for Disease Control and Prevention (CDC). Guidance for hospitals and acute care facilities reporting of respiratory pathogen, bed capacity, and supply data to CDC’s National Healthcare Safety Network (NHSN) Atlanta: CDC; 17 Nov 2023. Available from: https://www.hhs.gov/sites/default/files/covid-19-faqs-hospitals-hospital-laboratory-acute-care-facility-data-reporting.pdf
  18. Centers for Disease Control and Prevention CDC. FluView summary ending on May 25, 2004. Atlanta: CDC; 2024. Available from: https://www.cdc.gov/flu/weekly/weeklyarchives2023-2024/week21.htm
  19. Queensland Health. Queensland weekly influenza and Respiratory Syncytial Virus (RSV) surveillance report. Brisbane: Queensland Health; 2023. Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0009/1220400/influenza-rsv-qld.pdf
  20. Israel Center for Disease Control (ICDC). [Respiratory Viruses Surveillance Summary Report 2022-2023]. Ramat Gan: ICDC; 2023. Hebrew. Available from: https://www.gov.il/he/departments/publications/reports/flu-2022-2023
  21. Glatman-Freedman A, Kaufman Z, Kopel E, Bassal R, Taran D, Valinsky L, et al. Near real-time space-time cluster analysis for detection of enteric disease outbreaks in a community setting. J Infect. 2016;73(2):99-106.  https://doi.org/10.1016/j.jinf.2016.04.038  PMID: 27311747 
  22. Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, et al. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev. 2020;33:35-44. PMID: 31060948 
  23. Israel Ministry of Health. Palivizumab Vaccines. Jerusalem: Israel Ministry of Health; 29 Jul 2021. Available from: https://www.gov.il/en/departments/news/29072021-03
Hospital surveillance of respiratory viruses during the COVID-19 pandemic and beyond: contribution to the WHO mosaic framework, Israel, 2020 to 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Lea++Gur-Arie&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gur-Arie Lea </a>, <a href="/search?value1=Michal+Stein&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Stein Michal</a>, <a href="/search?value1=Hanna+Sefty&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sefty Hanna</a>, <a href="/search?value1=Ilana+S+Fratty&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fratty Ilana S</a>, <a href="/search?value1=Ital+Nemet&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nemet Ital</a>, <a href="/search?value1=Limor+Kliker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kliker Limor</a>, <a href="/search?value1=Nofar+Atari&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Atari Nofar</a>, <a href="/search?value1=Neta+S+Zuckerman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zuckerman Neta S</a>, <a href="/search?value1=Alina+Rosenberg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rosenberg Alina</a>, <a href="/search?value1=Heftziba+Ivgi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ivgi Heftziba</a>, <a href="/search?value1=Orit+Golan-Shany&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Golan-Shany Orit</a>, <a href="/search?value1=Nadav+Sorek&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sorek Nadav</a>, <a href="/search?value1=Orna+Schwartz-Harari&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Schwartz-Harari Orna</a>, <a href="/search?value1=Michal+Bromberg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bromberg Michal</a>, <a href="/search?value1=Lital+Keinan-Boker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Keinan-Boker Lital</a>, <a href="/search?value1=Michal+Mandelboim&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mandelboim Michal</a>, <a href="/search?value1=Aharona+Glatman-Freedman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Glatman-Freedman Aharona</a>, <a href="/search?value1=on+behalf+of+the+Israeli+Respiratory+Viruses+Hospital+Laboratory+Network+%28IRVHLN%29&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the Israeli Respiratory Viruses Hospital Laboratory Network (IRVHLN)</a></span>. Hospital surveillance of respiratory viruses during the COVID-19 pandemic and beyond: contribution to the WHO mosaic framework, Israel, 2020 to 2023. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(32):pii=2300634. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.32.2300634" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.32.2300634</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 15 Nov 2023;&nbsp;&nbsp; <span class="generated">Accepted</span>: 28 Apr 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.32.2300634
/content/10.2807/1560-7917.ES.2024.29.32.2300634
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error